Author

R. Womersley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Adem· 2 shared I. Muller· 2 shared J. A. Cotton· 2 shared M. Kaforou· 2 shared M. Levin· 2 shared P. Kropf· 2 shared S. U. Franssen· 2 shared Y. Takele· 2 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Adem

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivNov 1, 2021

Impaired in vitro Interferon-γ production in patients with visceral leishmaniasis is improved by inhibition of PD1/PDL-1 ligation

Y. Takele, E. Adem, S. U. Franssen…·P. Kropf

This study shows that PD1/PDL-1 inhibition increases IFN-γ production in VL patients, suggesting potential for immune checkpoint therapy.

DOI 10.1371/journal.pntd.0010544

humanflow cytometry

𝕏 PostBluesky

ImmunologybioRxivMar 30, 2021

Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV

Y. Takele, T. Mulaw, E. Adem…·P. Kropf

The paper identifies three immunological markers that predict visceral leishmaniasis relapse in HIV co-infected patients, showing they are more predictive than clinical features.

DOI 10.1016/j.xcrm.2021.100487

humanclinical cohort / trial

𝕏 PostBluesky